<DOC>
	<DOCNO>NCT02941068</DOCNO>
	<brief_summary>This prospective intend observe influence prophylactic empirical anti-fungal treatment Severe Sepsis patient perforation . With consent patient ' legal guardian prophylactic use antifungal agent , patient divide two group : prophylactic group Empirical group .</brief_summary>
	<brief_title>Influence Prophylactic Empirical Anti-fungal Treatment Severe Sepsis Patients With Perforations</brief_title>
	<detailed_description>Intra-abdominal perforation high risk fungal infection . The flora digestive tract would colonize go blood develop severe bacteria fungal infection intra-abdominal perforation one-third patient gastrointestinal perforation anastomotic leakage ICU develop intra-abdominal fungal infection . In particular , severe sepsis arisen infection could increase mortality . However , empiric/preemptive treatment study fail improve prognosis study address influence prophylactic anti-fungal treatment patient GI Perforation .</detailed_description>
	<mesh_term>Sepsis</mesh_term>
	<mesh_term>Fluconazole</mesh_term>
	<mesh_term>Caspofungin</mesh_term>
	<criteria>1. age ≥16 year 2. time gastrointestinal perforation anastopmotic leakage ( ) abdominal surgery enter ICU within 6 hour 3 . ICU stay least 5 day 4 . APACHE Ⅱ score within 24 hour randomization 16 5. severe sepsis 6. write informed consent 1. document fungus gastrointestinal perforations/anastopmotic leakage ( ) ongoing antifungal treatment study ; 2. fluconazole/caspofungin allergy ; 3. pregnant lactate woman ; 4. life expectancy 48 hour less .</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>severe sepsis</keyword>
	<keyword>intra-abdominal perforation</keyword>
	<keyword>surgical intensive care unit</keyword>
	<keyword>fungal infection</keyword>
	<keyword>prophylactic anti-fungal treatment</keyword>
</DOC>